ReviewFrontiers in systems biology2026
Mpox coinfections and clinical manifestation in Africa: a systematic review and meta-analysis.
Review in Frontiers in systems biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mpox remains a significant public health challenge in Africa, where endemic transmission persists alongside a high burden of other infectious diseases. Although the epidemiology and clinical impact of coinfections with human immunodeficiency virus (HIV) and varicella-zoster virus (VZV) remain poorly understood across the continent, these coinfections may influence clinical presentation, disease severity, and diagnostic accuracy. This aimed to describe the coinfections (VZV and HIV) patterns among confirmed mpox cases and characterize the trend of clinical presentation of mpox patients in Africa. Methods: Following PRISMA guidelines, we registered our protocol in PROSPERO (CRD420251133960) and conducted a systematic review and meta-analysis. We searched multiple electronic databases and grey literature through 27 February 2025, identifying observational studies from Africa that reported mpox coinfections (VZV and/or HIV) and associated clinical symptoms. Random-effects models were used to calculate pooled prevalence, while subgroup analyses and meta-regression explored sources of heterogeneity across WHO regions, countries, study designs, settings, and participant types. Results: A total of 23 studies conducted across African countries were included. The pooled prevalence of VZV-mpox coinfection was 8.73% (95% CI: 2.05-30.43; 10 studies; n = 2,681; Discussions: HIV and VZV coinfections with mpox pose a major yet possibly underestimated burden in Africa and are linked to more severe clinical presentations, particularly in hospital environments. The necessity of including clinical, epidemiological, and genomic in mpox monitoring systems is underscored by observed clinical differences across clades. Improving patient management and outbreak preparedness across the continent requires strengthening diagnostic capacity and routinely screening for coinfections. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251133960, identifier CRD420251133960.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.